10-Q: Odysight.ai Q3 Loss Widens Amid Revenue Drop, Strategic Shift

Odysight.ai reported a significant increase in net loss for Q3 2025 and the nine months ended September 30, driven by a major customer loss and increased operating expenses, despite a successful capital raise.

Summary

• Net loss for the nine months ended September 30, 2025, increased by 55% to $12.76 million, compared to $8.21 million in the prior year.
• Third-quarter 2025 net loss rose 54% to $4.42 million from $2.87 million in Q3 2024.
• Revenue for the nine months decreased 3% to $2.58 million, while Q3 revenue plummeted 88% to $0.15 million, primarily due to the derecognition of a contract with a Fortune 500 medical company.
• Operating expenses surged, with Research and Development up 56% to $7.32 million, Sales and Marketing up 99% to $1.60 million, and General and Administrative up 39% to $5.47 million for the nine-month period.
• Successfully completed a public offering in February 2025, raising approximately $20.9 million in net proceeds and listing on the Nasdaq Capital Market.
• Cash and cash equivalents stood at $29.48 million as of September 30, 2025, up from $18.16 million at December 31, 2024.
• Backlog as of September 30, 2025, was $14.2 million, a slight decrease from $15.0 million at December 31, 2024.

Sentiment

Score: 3

Explanation: While the company secured significant funding and has strategic growth initiatives, the substantial increase in net loss and dramatic revenue decline, particularly in Q3, driven by the loss of a major customer, indicates significant operational challenges and a negative financial performance for the period. The positive cash position is primarily due to financing, not operational profitability.

Positives

• Successfully completed a public offering in February 2025, raising approximately $20.9 million in net proceeds.
• Common stock began trading on the Nasdaq Capital Market under the symbol ODYS in February 2025, enhancing market visibility and access to capital.
• Strong cash position with $29.48 million in cash and cash equivalents as of September 30, 2025, providing liquidity for at least the next 12 months.
• Experienced growing interest in technology from Israeli clients, including government agencies and R&D programs, potentially accelerating technology assimilation due to increased defense budgets and operational intensity.
• Established new subsidiaries: D. VIEW Ltd. in Israel (February 2024) for the local defense market and Odysight.Ai Eu S.r.l. in Italy (January 2025) for European expansion.
• Received approximately $130,000 in royalty-bearing grants from the Israel Innovation Authority to support production line enhancement.

Negatives

• Net loss for the nine months ended September 30, 2025, increased by 55% to $12.76 million from $8.21 million in the prior year.
• Third-quarter 2025 net loss increased by 54% to $4.42 million from $2.87 million in Q3 2024.
• Revenue for the three months ended September 30, 2025, decreased significantly by 88% to $0.15 million from $1.29 million in the prior year.
• Full derecognition of a contract liability ($1.7 million) and fulfillment asset ($0.957 million) related to a Fortune 500 medical company customer due to no expected future purchase orders, leading to a substantial revenue decline.
• Operating expenses increased across all categories: Research and Development up 56% to $7.32 million, Sales and Marketing up 99% to $1.60 million, and General and Administrative up 39% to $5.47 million for the nine-month period.
• Accumulated deficit increased to $58.73 million as of September 30, 2025, from $45.97 million at December 31, 2024.
• Backlog slightly decreased to $14.2 million as of September 30, 2025, from $15.0 million at December 31, 2024.

Risks

• The ongoing war in Israel and regional instability in the Middle East could adversely affect operations, supply chains, and financial condition, despite a recent ceasefire.
• Dependence on a limited number of customers for a substantial portion of revenue, as evidenced by the loss of the Fortune 500 medical company customer.
• Expectation to continue incurring significant Research and Development and other costs, requiring additional funding to achieve profitability.
• No assurance of maintaining operations at a level sufficient for investors to obtain a return or raising sufficient capital on acceptable terms.
• Potential for further dilution of equity ownership if additional capital is raised through equity financing.
• Risk of delays, reductions, or elimination of Research and Development programs or commercialization efforts if unable to raise capital when needed.
• Increased expenses associated with being a listed public company on Nasdaq.
• Security, political, and economic instability in the Middle East, including the war in Israel and conflict with Iran, could harm business.
• Impact of competition and new technologies in the vision-based sensor market.
• Risks related to product liability claims or product recalls.
• Overall global economic environment and trade tensions.

Future Outlook

The company expects to continue incurring significant research and development and other costs related to ongoing operations, requiring additional funding to achieve profitability. Expenses are projected to increase with the scale-up of Odysight TruVision solutions and commercialization efforts. Existing cash and cash equivalents are believed to fund operating plans for at least the next 12 months, but additional capital may be needed for business expansion or strategic investments.

Management Comments

• Our management believes the Company cash and cash resources will allow the Company to fund its operating plan through at least the next 12 months from the filing date of these interim condensed financial statements.
• We expect to continue to incur significant research and development and other costs related to its ongoing operations, requiring the Company to obtain additional funding to continue its future operations until becoming profitable.
• We expect that our research and development expenses will increase as we continue to develop our products and services and recruit additional research and development employees due to increased focus on R&D activities in the I4.0 domain.
• We expect that our sales and marketing expenses will increase as we expand our selling and marketing efforts in the I4.0 domain.
• The war [in Israel] has not had a material adverse effect on our business. We have experienced some minor disruptions to our routine work, including some difficulties in traveling outside of Israel and occasional rocket fire.
• We have experienced a growing interest in our technology from Israeli clients, including government agencies and R&D programs, which may lead to more rapid assimilation of our technology into relevant platforms than we had anticipated prior to the commencement of the war, positively affecting on our business activity.

Industry Context

Odysight.ai operates in the growing vision-based Predictive Maintenance (PdM) and Condition Based Monitoring (CBM) markets, leveraging AI and machine learning. The company's solutions are deployed in aerospace, Industry 4.0, transportation, and energy sectors, with existing applications in aviation and medical. The shift away from a major medical client indicates a strategic pivot or market challenge in that segment, while increased R&D and sales efforts in Industry 4.0 suggest a focus on industrial applications. The conflict in Israel, while a risk, has also spurred increased interest from local defense clients, aligning with global trends of enhanced defense spending and technological integration in military applications.

Comparison to Industry Standards

• The company's Odysight TruVision solution was successfully used by NASA, and NASA placed a repeat order, indicating high-level validation of its technology.
• Customers include the Israeli Air Force, Israeli Ministry of Defense, France-based Safran Aircraft Engines, and a global international defense contractor, suggesting a strong presence in critical defense and aerospace sectors.
• The company's focus on Industry 4.0 aligns with broader industry trends towards smart, interconnected systems for improved efficiency and productivity in manufacturing and industrial processes.
• The loss of a Fortune 500 medical company customer highlights the competitive and potentially volatile nature of the medical device market for specialized vision technology, contrasting with the more stable or growing defense sector engagements.

Management Changes

Corporate Governance

Legal Proceedings

• No material claims or actions pending against the company that could have a material adverse effect on results of operations, financial condition, or cash flows.

Related Party Transactions

• Moshe (Mori) Arkin, a major stockholder and director, participated in the March 2021 private placement ($20 million) and the July 2024 private placement ($10.3 million gross).
• The Phoenix Insurance Company Ltd. and Shotfut Menayot Israel Phoenix Amitim (Phoenix Insurance and Phoenix Amitim), participated in the March 2023 private placement ($14 million) and the July 2024 private placement ($10.3 million gross).
• Related parties balance of $230 thousand as of September 30, 2025, up from $120 thousand as of December 31, 2024.

Stakeholder Impact

• Shareholders: Significant dilution from recent public offering and previous private placements. Increased accumulated deficit impacts shareholder equity. Potential for further dilution if more capital is raised. Nasdaq listing provides increased liquidity and visibility.
• Employees: Increased stock-based compensation and recruitment of new employees (including a CFO) indicate growth in workforce and compensation incentives. Some employees called to military reserve duty due to the Israel war, causing minor disruptions.
• Customers: Loss of a major Fortune 500 medical company customer significantly impacted revenue. However, growing interest from Israeli defense clients suggests new opportunities.
• Creditors: The successful capital raise significantly improved the company's cash position, reducing immediate liquidity concerns.

Next Steps

• Continue to invest in research and development for new products and additional functionality, particularly in the Industry 4.0 domain.
• Expand selling and marketing efforts, especially in the Industry 4.0 domain.
• Recruit additional research and development and sales and marketing employees.
• Potentially acquire complementary businesses.
• Obtain additional funding to continue future operations until becoming profitable, if needed.
• Monitor the security situation in Israel and its impact on operations, supply chains, and client engagement.

Key Dates

Recommendation

While Odysight.ai successfully raised substantial capital and achieved a Nasdaq listing, providing a strong cash runway for the next 12 months, the financial performance for the period is concerning. The dramatic 88% decline in Q3 revenue and a 55% increase in net loss for the nine months, largely due to the loss of a major medical client, indicates significant operational challenges and a reliance on new market penetration. The company is in an investment phase, with surging R&D and S&M expenses aimed at the Industry 4.0 and defense sectors. The increased interest from Israeli defense clients is a positive, but the overall financial trajectory is negative. Investors should hold to observe if the strategic pivot and increased investments translate into tangible revenue growth and reduced losses in the coming quarters, especially given the geopolitical risks in Israel.

Keywords

Odysight.ai, ODYS, 10-Q, Quarterly Report, Financial Results, Net Loss, Revenue Decline, Public Offering, Nasdaq Listing, Predictive Maintenance, Condition Based Monitoring, Vision-based AI, Sensor Technology, Industry 4.0, Aerospace, Defense, Medical Devices, Israel War Impact, Capital Raise, R&D Expenses, Operating Loss, Backlog